A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT):: Targeted intensification without increased transplant-related toxicity.

被引：0
|
作者：
Fung, HC
Forman, SJ
Nademanee, A
Molina, A
Yamauchi, D
Speilberger, R
Kogut, N
Sahebi, F
Parker, P
Rodriguez, R
Krishnan, A
Popplewell, L
Wong, J
Raubitschek, A
机构：
[1] City Hope Comprehens Canc Ctr, Div Hematol BMG, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Radioimmunotherapy, Duarte, CA USA
[3] City Hope Comprehens Canc Ctr, Div Diagnost Radiol, Duarte, CA USA
[4] City Hope Kaiser Permanente, Reg BMT Program, Los Angeles, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
870
引用
收藏
页码：248A / 248A
页数：1
相关论文
共 10 条
  • [1] TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY (RIT) COMBINED WITH BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). GROUPE D'ETUDE DES LYMPHOMES DE L'ADULTE (GELA) STUDY Z-BEAM 2
    Fruchart, C.
    Tilly, H.
    Morschhauser, F.
    Sebban, C.
    Salles, G.
    Ferme, C.
    Van Hoof, A.
    Bordessoule, D.
    Bouabdallah, R.
    Delmer, A.
    Van Den Neste, E.
    Laurent, G.
    Picquenot, J. M.
    Fournier, M.
    Gisselbrecht, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 169 - 169
  • [2] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [3] A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
    Shimoni, Avichai
    Avivi, Irit
    Rowe, Jacob M.
    Yeshurun, Moshe
    Levi, Itai
    Or, Reuven
    Patachenko, Paulina
    Avigdor, Abraham
    Zwas, Tzila
    Nagler, Arnon
    CANCER, 2012, 118 (19) : 4706 - 4714
  • [4] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [5] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] The City of Hope experience with novel transplant regimens that incorporate standard and escalated dose 90Yttrium ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin's lymphoma (NHL):: Targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
    Nademanee, A
    Fung, H
    Molina, A
    Krishnan, A
    Rodriguez, R
    Popplewell, L
    Spielberger, RT
    O'Donnell, M
    Snyder, D
    Parker, P
    Stein, A
    Kogut, N
    Falk, P
    Sahebi, F
    Zain, J
    Saville, W
    Raubitschek, A
    Forman, SJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 28 - 28
  • [7] Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
    Zipp, Lisa
    Saliba, Rima M.
    Valverde, Rosamar
    Okoroji, Grace-Julia
    Korbling, Martin
    Samuels, Barry I.
    Abruzzo, Lynne V.
    Alousi, Amin M.
    Andersson, Borje S.
    Hosing, Chitra M.
    Erwin, Bill
    Anderlini, Paolo
    Popat, Uday R.
    Kebriaei, Partow
    Macapinlac, Homer A.
    Champlin, Richard
    Khouri, Issa F.
    BLOOD, 2011, 118 (21) : 875 - 876
  • [8] A multi-centre prospective randomized study comparing yttrium-90 ibritumomab tiuxetan (zevalin) and high-dose BEAM chemotherapy (Z-BEAM) versus BEAM alone prior to autologous stem cell transplantation in patients with aggressive lymphoma
    Shimoni, A.
    Avivi, I.
    Rowe, J. M.
    Yeshurun, M.
    Levi, I.
    Or, R.
    Patachenko, P.
    Avigdor, A.
    Zwas, T.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S35 - S36
  • [9] High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL):: Update of a phase I/II trial.
    Nademanee, A
    Forman, SJ
    Molina, A
    Kogut, N
    Fung, HC
    Yamauchi, D
    Anderson, AL
    Smith, D
    Liu, AN
    Raubitschek, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 559S - 559S
  • [10] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
1